A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 242 participants.

Also called NCT06749457

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 1/2
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • Parexel Registry lists this organization as a collaborator
Registry
  • NCT NCT06749457
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06749457. Randomized; quadruple masking; primary purpose prevention. Start 2024-12-30 (actual); primary completion 2027-03-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Acronym
PEAK
Condition
Staphylococcus Aureus
Intervention (Drug)
AZD7760
Intervention (Other)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Parexel (class: industry)

Record details

Record id
cardio:ct-nct06749457
Content hash
2c52a2c29c5fb7dcd4d2f821197bd278632f332570cda3ea97735fe14da3f41e